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Summary This study investigated the prognostic value of immunohistochemically detected cathepsin D expression in 103 invasive ductal
carcinomas of the breast at stages pTl and 2. We also assessed the association between cathepsin D expression and histomorphological
tumour subtypes (invasive ductal carcinoma with extensive intraductal component, multifocal tumour). Cathepsin D expression was examined
at two cut-off levels (positive and highly positive) and separately identified within the epithelial and stromal component of all tumours. Positive
and highly positive epithelial expression was detected in 32 (31.1%) and 20 (19.4%) patients respectively. Stromal expression was found in
35 (34%) and 19 (18.4%) cases respectively. Epithelial cathepsin D expression was associated with stage and nuclear grade, but not with
lymph node or oestrogen receptor status. Positive and highly positive epithelial cathepsin D expression showed significant prognostic value
for overall survival (P = 0.003 and 0.01) and recurrence-free interval (P = 0.04 and 0.02). Cathepsin D expression in stromal cells was not
associated with either several established prognostic factors or survival. Multivariate analysis revealed that cathepsin D expression failed to
be an independent predictor of patients' outcome. Cathepsin D expression shows no significant association with histomorphological subtypes
of breast cancer. Our study supports the prognostic impact of immunohistochemically detected cathepsin D expression in the epithelial
component of breast cancer.
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Cathepsin D is a ubiquitous lysosomal protease with important
functions in protein catabolism. Three forms of the enzyme are
known: 52 kDa procathepsin D, a 48-kDa intermediate form and
stable cathepsin D with a 34-kDa heavy and a 14-kDa light chain.
Oestrogen induces cathepsin D expression in breast cancer cells
(Rochefort et al, 1987). The enzyme plays a key role in metastatic
spread by promoting the destruction of normal tissue architecture
and in tumour growth by the influence of growth factors (Westley
and May, 1996). The prognostic value of cathepsin D in breast
cancer is still controversial. Although most authors agree that high
cathepsin D levels have a negative prognostic impact, the prog-
nostic value of cathepsin D in clinically relevant subgroups of
breast cancer patients has not been established (Rochefort, 1996).
Furthermore, the importance ofepithelial vs stromal expression of
cathepsin D within the tumour is unclear. The prognostic value of
cathepsin D expression in the various cell types within a tumour
remains to be established in further investigations (Cardiff, 1994;
Westley and May, 1996).
The cytosolic assay is a well-standardized method for the
quantification of enzyme expression. The immunohistochemical
method is not yet established for standardized quantification.
However, this method allows a differentiation between tumour,
stromal and non-tumour epithelial cell expression ofcathepsin D.
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The aim of this study was to investigate the prognostic value
of immunohistochemically detected cathepsin D expression in
tumour vs stromal tissue of 103 patients with invasive ductal carci-
nomas of the breast. Furthermore, we examined whether different
cut-off points of immunoreactivity, which have been reported
in previous studies, influence the prognostic significance of
cathepsin D.
Several histomorphological subtypes of breast cancer display
distinct growth patterns and behaviours of invasion (Tavassoli,
1992). In our study, we also examined the association between
cathepsin D expression and the histomorphological subtypes infil-
trating ductal cancer (IDC) with extensive intraductal component
(EIC) and multifocal breast cancer.
MATERIAL AND METHODS
We investigated 103 paraffin-embedded tumour specimens from
women with primary invasive ductal carcinoma of the breast at
stages pTl and 2. During the period 1980-87, all patients with
stage pT1 tumours underwent primary surgical treatment,
including conservative tumour excision, and radiotherapy and all
patients with stage pT2 tumours underwent radical mastectomy
and radiotherapy. Axillary dissection was performed in all
patients. In patients with positive lymph node status, adjuvant
chemotherapy was administered after radical surgery. Anti-
oestrogenic agents were given in patients with positive oestrogen
receptor status. The mean age of patients was 54 years (range
23-81 years). Forty-two patients were premenopausal, whereas 61
were post-menopausal.
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Table 1 Correlation of positive cathepsin D expression (CD+) and high cathepsin D immunoreactivity (CD++) in the epithelial tumour (TU) or tumour-
associated stroma (ST) of invasive ductal carcinomas of the breast with histological stage, differentiation, lymph node and oestrogen receptor status, presence
of extensive intraductal tumour component (EIC) and multifocal appearance
CD+ P- CD++ P- CD+ P- CD++ P-
n TU value TU value ST value ST value
Histological stage
pTl 59 22.0% 11.9%0 31.5%0 20.3%0
pT2 44 43.2% 0.02 29.5% 0.002 38.6% 0.4 15.9% 0.6
Histological grade
Low (Gl) 27 14.8%0 37%0 25.9%0 22.2%0
High (G2/3) 76 36.8% 0.03 25.0% 0.02 40.8 0.3 17.1% 0.6
Nodal status
Negative 70 27.1
0 18.6%0 31.4%0 18.6%0
Positive 33 394% 0.2 21.2% 0.8 39.4% 04 18.2% 0.9
Oestrogen receptor
Negative 63 37.0%0 22.2%0 29.6%0 14.8%0
Positive 40 32.4% 0.7 23.5% 0.9 44.1% 0.5 26.5% 0.2
EIC
Absent 75 32.9% 19.2% 37.0% 45.2%
Present 28 25.9% 0.5 18.5% 0.8 22.2% 0.2 29.6% 0.6
Tumour
Unifocal 85 32.9% 21.2% 36.5% 20.0%
Multifocal 18 22.2% 0.4 11.10% 0.6 22.2% 0.2 11.10% 0.7
Breast and axillary tissue sections were reviewed for tumour
type, stage, grade, nodal status, presence of EIC and multifocal
appearance of the tumour by two pathologists blinded to clinical
data. According to the guidelines by Schnitt et al (1984), patients
with a combination of intraductal carcinoma comprising 25% or
more of the area encompassed by the IDC and intraductal carci-
noma in the adjacent tissue were regarded as having tumours with
EIC. Multifocal tumours were diagnosed according to the defini-
tion by Tavassoli (1992). Oestrogen receptor status was evaluated
by immunoassay.
The median follow-up time was 78 months (range 11-172
months). During the observation period, 23 patients developed
locoregional recurrence and eight showed distant metastases. Four
patients had local recurrence and distant metastasis. Twenty-seven
patients died from the disease.
Immunohistochemistry
We performed immunohistochemistry using the primary antibody
to cathepsin D (Dako Polyclonal rabbit anti-cathepsin D; code no.
A561, Dako, Carpinteria, CA, USA). The specificity of this anti-
body was determined in a Western blot against purified cathepsin
B, H, L and D. The antibody showed no reaction with cathepsin
B, H or L. The antibody recognizes the 52-kDa precursor
(procathepsin D) and the 48-kDa intermediate, active form of
cathepsin D. The intracellular staining of the antibody proves
immunoreactivity ofthe precursor and ofthe activated form of the
enzyme in the cytoplasm.
All sections tested were routine formalin-fixed paraffin-
embedded samples. Paraffin sections were soaked in xylene to
remove paraffin and rehydrated in graded alcohol series (100% to
70%). To recover antigenicity, we used the 'Antigen Retrieval
System' (BioGenex, San Ramon, CA, USA) twice for 5 min in a
microwave (HM 146, Elektra Bregenz, Schwaz, Austria) on high
power (650 W). The sections were then washed in 10 mm phos-
phate-buffered saline (PBS) (pH 7.6). The sections were incubated
with cathepsin D antiserum at 1:300 dilution for 60 min at room
temperature and then for a further 30 min with biotinylated anti-
mouse and anti-rabbit link-antibody (Dako LSAB 2 Kit). After
rinsing in PBS, the sections were coated with streptavidin conju-
gated to alkaline phosphatase for 10 min. The sections were rinsed
in PBS, incubated with Fast Red chromogen (naphthol phosphate
substrate in Tris buffer, 5 mg Fast Red chromogen tablets,
BioGenex) and then washed in distilled water. The sections were
finally counterstained with haematoxylin and mounted. The
staining reaction was confined to the cytoplasm.
Control for the immunohistochemical reaction was performed
once in every staining run. Localization ofthe immunohistochem-
ical reaction and staining intensity was positive to the same degree
in all positive controls. The positive control slide was prepared
Table 2 Cathepsin D in invasive ductal carcinoma of the breast. Univariate
analysis for overall survival, recurrence-free interval, pathological stage,
histological grade and nodal status. Multivariate analysis for the prognostic
value of overall survival using the generalized Cox models including
pathological stage, histological grade and nodal status with the candidates:
positive cathepsin D (CD+) and high cathepsin D immunoreactivity (CD++) in
the epithelial tumour (TU) or the tumour-associated stroma (ST)
Univariate analysis Multivariate analysis
Recurrence-free Overall Overall Overall
interval survival survival survival
(P-value) (P-value) RRa (95% Clb) (P-value)
Histological stage 0.02 0.0001 3.9 (1.5-10.3) 0.004
Histological grade 0.006 0.0002 Monotone likelihood 0.0001
Nodal status 0.007 0.0001 2.8 (1.3-6.3) 0.01
CD+/TU 0.04 0.003 1.1 (0.4-3.0) 0.9
CD+/ST 0.2 0.06 1.7 (0.7-4.4) 0.3
CD++/TU 0.02 0.01 1.4 (0.6-3.3) 0.4
CD++/ST 0.7 0.08 1.3 (0.5-3.5) 0.6
aRelative risk. bConfidence interval.
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from breast skin tissue. In skin, the antibody labels sweat ducts and
glands. In the subcutaneous tissue, the antibody stains normal
myoepithelial cells of non-lactating mammary glands and cells of
epithelial hyperplasia or apocrine metaplasia within areas of fibro-
cystic change. Macrophages, fibroblasts and lymphocytes showed
occasional staining. The negative control slide was prepared from
the same tissue block as the specimen. Instead of using a primary
antibody, we used a non-immune rabbit serum (Dako code no.
X902, 69 mg ml-') diluted 1:600.
We used a semiquantitative method to determine immunoreac-
tivity. Epithelial tumour and stromal cell immunoreactivity were
scored separately. The stromal component contained predomi-
nantly tumour-associated macrophages, fibroblasts and lymphoid
cells. Immunoreactivity of < 10% of the tumour or stromal cells
was regarded as negative, immunoreactivity of > 10% was
regarded as positive. Positive staining reaction in > 30% was
referred to as high immunoreactivity. Each slide was examined by
two pathologists. There was an interobserver variability in the
assessment of staining. Agreement of the two observers occurred
in 93% ofthe slides, which represents a high degree ofconsistency
between the observers.
Statistical analysis
Where appropriate, results were analysed by the chi-squared test.
We calculated the survival and recurrence-free interval probabili-
ties by the product limit method of Kaplan and Meier (Kaplan and
Meier, 1958). Univariate analysis was assessed using the log-rank
test. For multivariate analysis, the Cox proportional hazards model
(Cox, 1972) was used to assess the independent effect ofcathepsin
D expression. The potential prognostic factor was added to a
model of known prognostic factors: pathological stage, histo-
logical grade and lymph node status. The specific breast cancer-
related survival was used in all analyses. Recurrence-free interval
was defined as the time elapsed between the primary surgical treat-
ment and the first verified metastasis or recurrence. All P-values
are results of two-sided tests. The BMDP statistical software
system (BMDP Statistical Software, Los Angeles, CA, USA,
1990) was used. P-values < 0.05 were considered statistically
significant.
RESULTS
Ofthe 103 IDCs of the breast studied, stage pT1 was present in 59
tumours (57.3%) and pT2 in 44 tumours (42.7%). We found low-
(GI), moderate- (G2) and high-grade (G3) tumours in 26.2%,
36.9% and 36.9% respectively. To simplify the statistical analysis,
grade 1 constituted the low-grade category, while nuclear grades 2
and 3 were combined into a high-grade category. Thirty-three
patients (32%) had a positive histological lymph node status. IDC
with EIC was diagnosed in 28 tumours (27.2%). Eighteen patients
(17.5%) showed multifocal tumours. Seven patients (6.8%)
presented with both histomorphological subtypes of breast cancer.
Oestrogen receptor status was positive in 40 (38.8%) and negative
in 63 (61.2%) cases.
We found positive granular, intracytoplasmic cathepsin D
immunostaining reaction in 32 epithelial tumours (31.1%) and in
35 stromal components of the tumour (34%). High immuno-
reactivity was evident in 20 epithelial tumours (19.4%) and in 19
stromal components (18.4%). Sixty cases (58.3%) did not stain.
Twenty-four cases (23.3%) showed expression of cathepsin D
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Figure 1 Kaplan-Meier overall survival analysis of patients with positive
(CD+, log-rank P = 0.003) and high cathepsin D (CD++, log-rank P = 0.01)
epithelial tumour expression compared with patients with negative results
(CD-, CD--)
in both the tumour and the surrounding stroma; high immuno-
reactivity was found in six of these cases (5.8%).
The statistical results of carcinomas with positive cathepsin D
expression were compared with cases with high immunoreactivity.
There was no difference in the statistical significance between
both groups regarding the association of cathepsin D expression
with established prognostic factors, IDC with EIC and multifocal
tumours (Table 1), and prognosis for overall survival and recur-
rence-free interval (Table 2).
The results of cathepsin D expression with tumour stage, grade,
nodal status, oestrogen receptor status, IDC with EIC and multi-
focal tumours are presented in Table 1. Data from the univariate
and multivariate analysis regarding overall survival and recur-
rence-free interval are shown in Table 2. The number of patients
was too small to consider pre- and postmenopausal or lymph node-
positive or -negative patients in a subgroup analysis. The survival
distribution function grouped by cathepsin D epithelial tumour
expression is shown in Figure 1.
DISCUSSION
Most biochemical studies of cathepsin D in breast cancer show
that elevated total tumour cathepsin D is an adverse prognostic
factor. Subgroup analysis regarding node-negative and node-posi-
tive tumours yielded controversial results (Spyratros et al, 1989;
Thorpe et al, 1989; Tandon et al, 1990; Westley and May, 1996).
The cytosolic assay is an established method for quantification of
total enzyme expression without differentiation between benign or
malignant, epithelial or stromal cell types. During recent years the
importance of the tumour cell stroma in the process of breast
cancer invasion has become more evident. Several proteases have
been shown to be active in stromal cells of malignant tumours
(Joensuu et al, 1995). In breast cancer, stromal cells such as
tumour-associated macrophages can overexpress cathepsin D
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along with epithelial tumour cells. Immunohistochemistry is a
precise method to localize the expression ofcathepsin D, but there
is no general agreement about the results of immunohistochemi-
cally detected cathepsin D expression in breast cancer (Cardiff,
1994; Westley and May, 1996). Therefore, the comparison of data
on cathepsin D, measured by cytosolic assay and immunohisto-
chemistry, must be interpreted with caution (Rochefort, 1996).
Although most of the immunohistochemical studies reported
immunostaining ofmacrophages in breast cancer, only a few ofthem
regarded stromal cathepsin D expression as relevant for the patients'
prognosis. Henry et al (1990) were the first group to describe high
levels of cathepsin D expression in stromal macrophages of breast
cancer patients. In this study, it was noted that stromal cells
contribute significantly to the levels of cathepsin D in tumour
cytosol. However, the prognostic value of enzyme expression in
macrophages was not analysed (Henry et al, 1990).
A number of studies have reported a poor prognosis for patients
with cathepsin D expression in an epithelial tumour. Winstanley et
al ( 1993) showed a prognostic difference in patients, depending on
node-positive or node-negative status. Another study analysed
cathepsin D tumour expression in node-negative cases and found a
significantly poorer prognosis regarding relapse-free and overall
survival in patients with cathepsin D-expressing tumours (Isola et
al, 1993). Kandalaft et al (1993) investigated cathepsin D tumour
expression in both node-positive and -negative patients and found
only a trend to poor prognosis for overall survival in node-positive
cases.
More recent studies have separately analysed the prognostic
value of cathepsin D expression in tumour cells and stroma. Two
studies reported no prognostic significance for overall survival
regarding tumour expression of cathepsin D, but decreased
survival in the entire group of patients with increased stromal
expression (Joensuu et al, 1995; O'Donoghue et al, 1995). Nadji et
al ( 1996) showed an association of stromal cathepsin D expression
and shorter disease-free and overall survival in node-negative
cases. Tetu et al (1993) found a trend for reduced relapse-free
survival in a study restricted to node-positive patients. Gohring et
al (1996) took immunoreaction in tumour cells and tumour-infil-
trating macrophages into account and showed a significant corre-
lation of cathepsin D expression with clinical outcome in
node-negative, but not in node-positive, patients. Other studies,
examining either both tumour and stromal or only tumour
cathepsin D expression, did not find any association with disease-
free or overall survival (Domagala et al, 1992; Armas et al, 1994).
In our study, cathepsin D expression in the epithelial tumour
shows a poor prognosis for overall survival and recurrence-free
interval in the univariate analysis. Stromal cathepsin D expression
had no prognostic impact. However, tumour cathepsin D expres-
sion had no independent prognostic value in the multivariate
analysis with established prognosticators.
A relationship between cathepsin D expression and well-estab-
lished prognostic factors, such as tumour stage, differentiation and
oestrogen receptor status, has been described in various studies. The
correlation with nodal status shows more controversial results and
should be examined in future investigations because of its strong
prognostic value (Westley and May, 1996). In our study, tumour
cathepsin D expression was associated with tumour stage and differ-
entiation but not with lymph node or oestrogen receptor status.
A variety of scoring methods have been used to assess the
immunohistochemical reaction of cathepsin D expression:
histoscores on the basis of intensity and number of stained cells
(Kandalaft et al, 1993), assessment of the proportion of cells
staining (Tetu et al, 1993) and assessment of overall positivity
(Henry et al, 1990; Isola et al, 1993; Winstanley et al, 1993;
O'Donoghue et al, 1995). Studies assessing overall positivity chose
different cut-offpoints ranging from 10% (Isola et al, 1993) to 25%
(O'Donoghue et al, 1995) for positive cathepsin D immunoreac-
tivity. To allow comparison ofour data with recent studies, we have
used two cut-off points (10% and 30%). Our study shows that
different cut-off levels of positive cathepsin D expression have no
influence on the statistical significance of the prognostic value
regarding cathepsin D expression in breast cancer.
Histological subtypes of IDC of the breast have an important
influence on therapy because oftheir unusual growth pattern. IDC
with EIC and multifocal tumours of the breast are reported to be
predictors of local recurrence after conservative surgery and radio-
therapy (Tavassoli, 1992; Schnitt et al, 1984). These subtypes
seem to have a different prognostic value when compared with no
otherwise specified (NOS) IDCs (Silverberg and Chitale, 1973;
Dawson, 1993). Cathepsin D plays an important role in promoting
the breakdown of the basal membrane and degrading the extracel-
lular matrix. The enzyme also shows an effect on cell proliferation
by growth stimulation (Westley and May, 1996). In our study,
cathepsin D expression had no association with histomorpho-
logical subtypes, e.g. IDC with EIC or multifocal tumours.
In conclusion, our results support the assumption that stromal
cathepsin D expression has no prognostic impact irrespective of
the staining intensity. This is also underlined by the fact that
stromal cathepsin D expression is not correlated with histo-
morphological tumour subtypes displaying pronounced growth
patterns. Although we have found that epithelial cathepsin D
expression is associated with a short overall and disease-free
survival, it does not yield additional prognostic information in a
multivariate model with established prognosticators.
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